• Cofoe Medical Technology seeks shareholder approval to appoint Ernst & Young (EY Hong Kong) as overseas auditor for FY2026.
• Mandate to start after the 2026 third extraordinary general meeting, running through the next annual general meeting.
• Board vote on Aug. 28, 2026 backed the proposal, following an Audit Committee recommendation citing independence, capability, and audit quality.
• Overseas audit fees estimated at RMB 1.4 million to RMB 1.8 million, subject to engagement terms and stable operating conditions.
• Management authorization sought to execute the audit engagement agreement with EY Hong Kong.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cofoe Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304485), on August 28, 2026, and is solely responsible for the information contained therein.